Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel anti-PD-1 antibody can be given subcutaneously

Publish date:: May 31, 2019

Key clinical point: Subcutaneous delivery of a novel anti–programmed cell death antibody showed positive safety and efficacy outcomes in patients with advanced solid tumors.

Major finding: The overall response rate was 18.4% and no dose-limiting toxicities were detected in both intravenous and subcutaneous groups.

Study details: A phase 1 dose-escalation study of 40 patients with advanced solid tumors.

Disclosures: The study was funded by Pfizer. The authors reported financial affiliations with BerGenBio, EMD Serono, Janssen, Mirati Therapeutics, Pfizer, and several others.

Citation:

Johnson ML et al. JAMA Oncol. 2019 May 30. doi: 10.1001/jamaoncol.2019.0836.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immuno-oncology

Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors,

Dual immunotherapy goes the distance in MSI-H colorectal cancer,

T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,